Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 399 for:    PYY

The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02413762
Recruitment Status : Unknown
Verified March 2015 by Imperial College London Diabetes Centre.
Recruitment status was:  Recruiting
First Posted : April 10, 2015
Last Update Posted : April 10, 2015
Sponsor:
Information provided by (Responsible Party):
Imperial College London Diabetes Centre

Brief Summary:
This study aims to investigate the potential of the gut hormones GLP-1, PP, PYY and the iron regulatory hormone hepcidin as biomarkers for progression to complications in diabetes mellitus.

Condition or disease Intervention/treatment
Diabetes Mellitus, Type 2 Other: No intervention

Detailed Description:

Iron overload and mechanisms inducing insulin resistance are reciprocally linked. Dietary iron absorption, and iron uptake in liver and adipose tissue, are regulated through the hormone hepcidin. Iron is implicated in microvascular and macrovascular disease pathways and therefore hepcidin may represent a biomarker for progression to complications in type 2 diabetes mellitus.

Serum pancreatic polypeptide levels correlate with visceral adiposity and may therefore contribute to the diagnosis of, and risk stratification in, the metabolic syndrome.

Hypothesis:

Measuring iron status, incretin hormones and serum pancreatic polypeptide will facilitate discrimination of patients at risk of vascular complications of T2DM and clinically significant non-alcoholic fatty liver disease.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
Study Start Date : March 2015
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Group/Cohort Intervention/treatment
NGT, no insulin resistance
Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
IFG/IGT/T2DM
Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
Insulin resistance without IGT
e.g. polycystic ovarian syndrome. No intervention.
IGT, no insulin resistance
e.g. T1DM. No intervention.
Previous metabolic surgery
Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
Other: No intervention
No intervention




Primary Outcome Measures :
  1. Vascular complications of diabetes mellitus [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Progression to NAFLD or NASH [ Time Frame: 2 years ]

Biospecimen Retention:   Samples Without DNA
Blood plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adults resident in the UAE, attending ICLDC for normal healthcare.
Criteria

Inclusion Criteria:

  • all

Exclusion Criteria:

  • lack of capacity for informed consent; vulnerable individuals

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02413762


Contacts
Layout table for location contacts
Contact: Nader Lessan, MBBS FRCP MD +971 2 404 0800 nlessan@icldc.ae
Contact: Adam J Buckley, MRCP MRes +971 2 404 0800 ext 504 abuckley@icldc.ae

Locations
Layout table for location information
United Arab Emirates
Imperial College London Diabetes Centre Recruiting
Abu Dhabi, United Arab Emirates, 48338
Contact: Nader Lessan, MBBS MD FRCP    +971 2 404 0800    nlessan@icldc.ae   
Contact: Adam J Buckley, MRCP MRes    +971 2 404 0800 ext 504    abuckley@icldc.ae   
Principal Investigator: Nader Lessan, MBBS MD FRCP         
Sub-Investigator: Adam J Buckley, MRCP MRes         
Sponsors and Collaborators
Imperial College London Diabetes Centre
Investigators
Layout table for investigator information
Principal Investigator: Nader Lessan, MBBS FRCP MD Imperial College London Diabetes Centre

Publications:
Layout table for additonal information
Responsible Party: Imperial College London Diabetes Centre
ClinicalTrials.gov Identifier: NCT02413762     History of Changes
Other Study ID Numbers: IREC019
First Posted: April 10, 2015    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hormones
Hepcidins
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Infective Agents